News articles about Maximus (NYSE:MMS) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Maximus earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave press coverage about the health services provider an impact score of 46.3781575692602 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
A number of research firms have recently weighed in on MMS. Zacks Investment Research raised Maximus from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a report on Tuesday, February 13th. Canaccord Genuity cut their price target on Maximus from $71.00 to $65.00 and set a “hold” rating for the company in a report on Friday, February 9th. Finally, Maxim Group reissued a “hold” rating and issued a $69.00 price target (up from $66.00) on shares of Maximus in a report on Thursday, February 8th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $66.60.
Shares of Maximus stock opened at $68.11 on Monday. The company has a market capitalization of $4,442.36, a price-to-earnings ratio of 20.27, a PEG ratio of 2.27 and a beta of 1.18. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.57 and a quick ratio of 2.57. Maximus has a 1 year low of $57.12 and a 1 year high of $72.71.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 28th. Stockholders of record on Thursday, February 15th were given a $0.045 dividend. This represents a $0.18 dividend on an annualized basis and a dividend yield of 0.26%. The ex-dividend date of this dividend was Wednesday, February 14th. Maximus’s dividend payout ratio is currently 5.36%.
In other Maximus news, Director Russell A. Beliveau sold 1,000 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $71.73, for a total transaction of $71,730.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Richard A. Montoni sold 10,000 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $67.42, for a total value of $674,200.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 44,600 shares of company stock valued at $3,014,830. Company insiders own 2.48% of the company’s stock.
MAXIMUS, Inc provides business process services (BPS) to government health and human services programs in the United States, the United Kingdom, Australia, Canada, Singapore, and Saudi Arabia. The company's Health Services segment offers various BPS, appeals, and assessments, as well as related consulting services for state, provincial, and national government programs comprising Medicaid, Children's Health Insurance Program, the Affordable Care Act, Health Insurance British Columbia, the Health Assessment Advisory Service, and Preadmission Screening and Resident Reviews.
Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.